Beyond Air, Inc. (NASDAQ:XAIR) CEO Steven A. Lisi Purchases 1,476,626 Shares

Beyond Air, Inc. (NASDAQ:XAIR) CEO Steven A. Lisi bought 1,476,626 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The shares were bought at an average cost of $0.50 per share, with a total value of $738,313.00. Following the completion of the purchase, the chief executive officer now directly owns 3,249,411 shares of the company’s stock, valued at approximately $1,624,705.50. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Beyond Air Trading Down 22.2 %

XAIR stock traded down $0.09 during midday trading on Tuesday, reaching $0.30. 1,378,241 shares of the company traded hands, compared to its average volume of 509,031. The firm has a market capitalization of $13.86 million, a price-to-earnings ratio of -0.17 and a beta of -0.11. Beyond Air, Inc. has a 52-week low of $0.30 and a 52-week high of $2.61. The business has a 50 day moving average of $0.44 and a 200-day moving average of $0.91. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.42 and a current ratio of 2.63.

Beyond Air (NASDAQ:XAIR) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.12. The business had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $0.72 million. Beyond Air had a negative net margin of 3,272.46% and a negative return on equity of 240.15%. During the same quarter in the previous year, the business posted ($0.45) earnings per share. As a group, sell-side analysts expect that Beyond Air, Inc. will post -1.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on XAIR. Piper Sandler cut their price objective on Beyond Air from $3.50 to $1.00 and set an “overweight” rating for the company in a research report on Wednesday, August 7th. Roth Mkm reissued a “buy” rating and set a $2.00 price target on shares of Beyond Air in a research note on Friday, August 16th. Roth Capital raised Beyond Air to a “strong-buy” rating in a research note on Friday, August 16th. Finally, BTIG Research downgraded Beyond Air from a “buy” rating to a “neutral” rating in a research report on Tuesday, June 25th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Beyond Air currently has an average rating of “Buy” and a consensus target price of $3.67.

Institutional Trading of Beyond Air

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XAIR. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Beyond Air during the second quarter worth $47,000. Gendell Jeffrey L lifted its holdings in Beyond Air by 2.8% during the 4th quarter. Gendell Jeffrey L now owns 1,120,297 shares of the company’s stock valued at $2,196,000 after buying an additional 30,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Beyond Air by 5.0% in the 1st quarter. Vanguard Group Inc. now owns 1,399,298 shares of the company’s stock worth $2,435,000 after acquiring an additional 66,224 shares in the last quarter. 31.50% of the stock is owned by hedge funds and other institutional investors.

About Beyond Air

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.